KnowBreastCancer StopBreastCancer Learn the Facts. Know the Evidence. Become an Advocate. Brought to you by NBCC
 

Month: June 2012

FDA approves new drug for the treatment of HER2+ metastatic breast cancer

On June 8, the FDA approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2+ metastatic breast cancer. According to the FDA, the drug is intended for patients who have not received prior treatment for metastatic breast cancer with an anti-HER2 therapy or chemotherapy and is to be combined with trastuzumab, another anti-HER2 […]